Dr. Hamilton on Prognostic Impact of Molecular Mutations in AML and MDS on HCT Outcomes

Name: Dr. Hamilton on Prognostic Impact of Molecular Mutations in AML and MDS on HCT Outcomes
Uploaded: 2016-01-29T13:47:00.000Z
Description: Betty Hamilton, MD, associate staff physician, Department of Hematologic Oncology and Blood Disorders and Blood and Marrow Transplant Program, discusses the prognostic impact of molecular mutations in acute myeloid leukemia and myelodysplastic syndromes on allogeneic hematopoietic cell transplant outcomes and the adverse impact of TET2 mutations.

January 29, 2016

Betty Hamilton, MD

Video

Conference|ASH Annual Meeting and Exposition

Betty Hamilton, MD, associate staff physician, Department of Hematologic Oncology and Blood Disorders and Blood and Marrow Transplant Program, discusses the prognostic impact of molecular mutations in acute myeloid leukemia and myelodysplastic syndromes on allogeneic hematopoietic cell transplant outcomes and the adverse impact of TET2 mutations.

Betty Hamilton, MD, associate staff physician, Department of Hematologic Oncology and Blood Disorders and Blood and Marrow Transplant Program, discusses the prognostic impact of molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on allogeneic hematopoietic cell transplant (HCT) outcomes and the adverse impact of TET2 mutations.

In a study, next-generation sequencing was used in 123 patients to evaluate the most commonly recurring mutations in MDS and AML, and what their prognostic impacts were on outcomes after HCT, Hamilton explains.

Results showed that TET2 mutations were reported to be a predictor for poor survival following HCT. In addition, the presence of complex karyotype, ASXL1, DNMT3A, and p53 mutations is also associated with poor overall and relapse-free survival. Analyses are ongoing to validate these findings and consider other factors, Hamilton adds.